VLS Valneva SE

VALNEVA Declaration of shares and voting rights: February 28, 2025

VALNEVA Declaration of shares and voting rights: February 28, 2025

VALNEVA

Declaration of shares and voting rights

February 28, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: March 5, 2025

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**






162,521,524 



ordinary shares with a par value of €0.15 each





178,408,022Double voting rights granted on 907 ordinary shares









Transfer into bearer form of 142 shares with double voting rights
Between February 7 & February 21, 2025









Between February 6 & February 14, 2025
178,283,700

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
05/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

VALNEVA Declaration of shares and voting rights: February 28, 2025

VALNEVA Declaration of shares and voting rights: February 28, 2025 VALNEVA Declaration of shares and voting rights February 28, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: March 5, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal numbe...

 PRESS RELEASE

VALNEVA Déclaration d’actions et de droits de vote : 28 février 2025

VALNEVA Déclaration d’actions et de droits de vote : 28 février 2025 VALNEVA Déclaration d’actions et de droits de vote 28 février 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 5 mars 2025 Nombre d’actions composant le capital de ValnevaNombre total de droits de vote incluant les droits de vote suspendus*Origine de la variationDate à laquelle cette variation a été con...

Oscar Haffen Lamm
  • Oscar Haffen Lamm

Valneva: CHMP positive opinion on Ixchiq's label extension in adolesce...

Friday Valneva announced the positive opinion of the CHMP regarding the label extension of Ixchiq to adolescents (aged 12-18 y.o). The next step will be for the EC to review the CHMP recommendation, with a decision on approval within 60 days. As a reminder, the decision is supported by 6-months ado

 PRESS RELEASE

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Health...

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences Saint-Herblain (France), March 3, 2025 – (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Bühler will present at the TD Cowen 45th Annual Health Care Conference, taking place March 3 - 5, 2025, in Boston, MA. Mr. Lingelbach and Mr. Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen ...

 PRESS RELEASE

Valneva fera une présentation lors des conférences investisseurs TD Co...

Valneva fera une présentation lors des conférences investisseurs TD Cowen et Van Lanschot Kempen Saint-Herblain (France), le 3 mars 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que des membres de son équipe dirigeante participeront à des conférences investisseurs aux États-Unis et en Europe. Thomas Lingelbach, directeur général de Valneva, et Peter Bühler, directeur financier, feront une présentation lors de la 45ème « TD Cowen Annual Healthcare Conference » qui se tiendra du 3 au 5 mars 2025 à Boston, États-Unis. Thomas Lingelbach ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch